Frontlight ResearchEarly access
CompletedNo phase
Investigation of the Safety and Effectiveness of a Trifocal IOL
Key facts
- Who runs it
- Beaver-Visitec International, Inc.
- Where
- Alexandria, Bloomington, Bozeman, Brecksville, Dallas, Indianapolis, Las Vegas, Lynchburg, Nacogdoches, Northridge, Omaha, Orange, Orland Park, Salt Lake City, San Antonio, Sioux Falls, St Louis, Vineland, West Fargo, and West Mifflin, United StatesSee the 20 sites
- Trial code
- Status
- Completed
- People taking part
- 539 people enrolled
- Started
- 28 Apr 2022
- Ended
- 13 May 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- FINEVISION HP IOL
- Alcon AcrySof SN60AT
- Record updated
- 29 January 2025
Who can take part
- Age
- 22 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Male or female adults, age 22 years or older at the Preoperative Visit
- Visually significant cataracts in both eyes that are eligible for phacoemulsification cataract surgery
- Willing to undergo cataract surgery in the second operative eye within 7 - 30 days after surgery in the first eye
- Projected Best Corrected Distance Visual Acuity (BCDVA) of 0.2 logMAR (20/32 Snellen) or better in each eye after cataract surgery/IOL implantation, as determined by the medical judgement of the Investigator
- Eligible for receipt of an IOL power within the range of the investigational IOL (+10.0 D to +30.0 D, in 0.50 D increments) in each eye
- Contact lens users must be willing to discontinue wear of their lenses in accordance with the following requirements:; Rigid gas permeable lenses for ≥ 7 days prior to the Preoperative Visit; Soft contact lenses for ≥ 3 days prior to the Preoperative Visit Contact lens wearers must demonstrate a stable refraction (within ±0.50 D for both sphere and cylinder) in each eye, as determined by manifest refraction on two consecutive examination dates at least one week apart after discontinuation of contact lens wear
- Provide signed written consent prior to participation in any study-related procedures
- Ability, comprehension, and willingness to follow study instructions, and likely to complete all study visits
- Female subjects must be 1-year postmenopausal, surgically sterilized, or, if of childbearing potential, have a negative urine pregnancy test at the Preoperative Visit. Women of childbearing potential must use an acceptable form of contraception throughout the study. Acceptable methods include at least one of the following: intrauterine (intrauterine device), hormonal (oral, injection, patch, implant, ring), barrier with spermicide (condom, diaphragm), or abstinence
Who cannot take part
- Reasonably expected to require secondary ocular surgical intervention or laser treatment other than YAG capsulotomy in either eye during the study participation period
- Previous intraocular, corneal, or retinal detachment surgery, including corneal transplant, LASIK, astigmatic keratotomy and limbal relaxing incisions in either eye
- Clinically significant ocular inflammation or infection present ≤ 30 days in either eye prior to the Preoperative Visit
- Use of medications known to interfere with visual performance, pupil dilation, or iris structure ≤ 30 days prior to the Preoperative Visit
- Participation in any study of an investigational, interventional product within 30 days prior to the Preoperative Visit or at any time during the study period
- History or presence of, or predisposition to, degenerative visual disorders (e.g., macular degeneration, retinal detachment, proliferative diabetic retinopathy, or other retinal disorders) predicted to result in BCDVA worse than 0.2 LogMAR (20/32 Snellen) in either eye during the study participation period
- Significant anterior segment pathology in either eye that might increase intraoperative risk or compromise IOL stability (e.g., pseudoexfoliation syndrome)
- Presence or history of one or more severe/serious ocular conditions (e.g., glaucoma, uveitis, ocular infection, severe dry eye) in either eye, or any other unstable medical condition (e.g., uncontrolled diabetes) that in the opinion of the Investigator would put the subject's health at risk, confound the results of the study and/or prevent the subject from completing all study visits
- Presence of one or more clinically significant corneal abnormalities in either eye, including corneal dystrophy, irregularity, or edema per the Investigator's medical opinion
- Rubella, congenital, traumatic or complicated cataract in either eye
- Preoperative keratometric astigmatism > 1.0 D or irregular corneal astigmatism in either eye (Note: corneal incisions intended to reduce astigmatism are not permitted)
- Pregnant or nursing females
Where in United States
- Vance Thompson Vision, MN SiteAlexandria, United States
- Chu Vision InstituteBloomington, United States
- Vance Thompson Vision, MT SiteBozeman, United States
- Cleveland Eye ClinicBrecksville, United States
- Key-Whitman Eye CenterDallas, United States
- Michael Washburn Center for Ophthalmic ResearchIndianapolis, United States
- Center for SightLas Vegas, United States
- Piedmont Eye CenterLynchburg, United States
- Lehmann Eye CenterNacogdoches, United States
- Mitchell C Shultz MD/Shultz Chang VisionNorthridge, United States
- Vance Thompson Vision NE SiteOmaha, United States
- Coastal Vision Medical GroupOrange, United States
- Arbor Centers for Eye CareOrland Park, United States
- The Eye Institute of UtahSalt Lake City, United States
- Parkhurst NuVisionSan Antonio, United States
- Vance Thompson Vision. SD SiteSioux Falls, United States
- Ophthalmology Consultants LtdSt Louis, United States
- Eye Associates & SurgiCenterVineland, United States
- Vance Thompson Vision ND SiteWest Fargo, United States
- Associates in Ophthalmology LtdWest Mifflin, United States
About the trial
What the trial wants to find out
This study is a prospective, multicenter, randomized, double masked confirmatory trial comparing an investigational trifocal intraocular lens (IOL) and a commercially available monofocal IOL.
The 2 groups in the trial
- FINEVISION HPTreatment being tested
Trifocal FINEVISION HP. Cataractous lens will be removed in the study eyes and the FINEVISION HP will be implanted in the capsular bag.
Treatment: FINEVISION HP IOL
- Control ProductExisting treatment, for comparison
Cataractous lens will be removed in the study eyes and the Alcon AcrySof® SN60AT IOL will be implanted in the capsular bag.
Treatment: Alcon AcrySof SN60AT
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Investigation of the Safety and Effectiveness of FINEVISION HP Trifocal IOL
- Record updated
- 29 January 2025